Share your thoughts with us!

At Fin, going all-in on AI wasn't a moonshot — it was a calculated bet that doing nothing was the greater risk. And steering the financial strategy behind that decision was CFO Dan Griggs.

On this episode of Ventured Growth, Catherine Jhung sits down with Dan to explore how Fin transformed from a traditional SaaS help desk into one of the most talked-about AI-native platforms in enterprise software. With a career spanning Nestlé, RocketFuel and Sitecore, Dan brings a rare mix of operational depth and financial discipline to one of the boldest pivots in SaaS.

Dan also talks about the decision to overhaul their entire pricing model at the risk of cannibalizing existing revenue, how he thinks about forecasting in an outcome-based world, and what the role of CFO looks like when the pace of change never slows down.

Topics include:

* Fin's all-in bet on AI and what it took to get there
* Overhauling a pricing model mid-flight to outcome-based revenue
* How Fin forecasts in a usage-driven, AI-native business
* Resource allocation and the internal debate around hiring vs. automation
* Why $250 million in debt financing made more sense than equity
* What the CFO role looks like in a company transforming at speed
* And more...

Dan Griggs is the CFO of Fin, where he leads financial planning and analysis, and accounting, drawing on more than 15 years in financial and leadership roles across high-growth technology companies. He previously served as CFO at Sitecore, where he helped transition the business to subscription-based cloud software while doubling revenue, and as VP of Financial Planning and Analysis at Rocket Fuel, where he drove over $400M in revenue growth and a successful IPO.

Intercom rebranded to Fin on May 12, 2026. This conversation took place prior to the rebrand, so the episode refers to the company as Intercom throughout.

Share your thoughts with us!

At Akcea Therapeutics, biotech leadership meant more than drug development—it meant building with purpose, addressing long-overlooked areas of health, and paving the way for future leaders. And at the helm was founding CEO Paula Soteropoulos.

On this episode of Ventured Growth, Katie Segien sits down with Paula to explore how she helped take Akcea public, launched therapies for underserved diseases, and advanced efforts in women’s health—a space historically underfunded and under-researched. With 35 years of experience across pharma and biotech, Paula shares how she's using her platform to drive both innovation and inclusion.

She also talks about mentoring the next generation of women CEOs, shaping boardroom dynamics, and why genomic medicine could help close longstanding gaps in women’s care.

Topics include:

• Leading Akcea through IPO and pivotal drug launches
• The massive underfunding of research into women’s health
• Mentoring and elevating women in biotech leadership
• Building purpose-driven executive teams
• What’s next in in vivo genomic medicine
• And more…
  
  
  

Paula Soteropoulos is a seasoned biotech executive, board member and advisor whose career spans a broad range of therapeutic areas, including rare disease, cardiovascular and metabolism, infectious disease, renal, and transplant and oncology. Paula is a Venture Partner at 5AM Ventures, and serves as Chairman of Ensoma, and on the boards of directors of Dianthus Therapeutics, Rallybio, and Kyowa Kirin. Paula was the founding CEO of rare disease therapeutic developer, Akcea Therapeutics, and was a board director at UniQure. She serves on the advisory boards for Chiesi USA and Tufts University Department of Chemical and Biological Engineering. Paula continues to lead and advise companies at the intersection of science, leadership, and women’s health.

Share your thoughts with us!

At Eight Sleep, product innovation isn’t just about comfort—it’s about performance, health, and personalization at scale. And behind the numbers powering that mission is CFO Nick Chammas.

On this episode of Ventured Growth, Catherine Jhung sits down with Nick to discuss how Eight Sleep evolved from a niche product for athletes into a sleep fitness brand with global momentum. From raising $100M to expanding manufacturing across continents, Nick has helped steer the company through pivotal growth milestones.

He shares insights into their new AI-powered sleep agent, how digital twins are driving personalized rest, and why the best product feedback comes straight from the customer.

Topics include:

• Applying AI to sleep and biometric data
• From product-market fit to global expansion
• How Eight Sleep is solving for menopause, snoring, and temperature regulation
• Leading a capital-efficient team of 100
• Nick’s personal journey from banking to scaling a hardware brand
• And more…

Nick Chammas is the CFO of Eight Sleep, the world’s first sleep fitness company. With experience across finance, operations, and strategy, he brings a holistic view to driving growth in a competitive consumer tech landscape.